Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebocontrolled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome

HS 2013-9339
Heart, Diabetes
Shaista Malik, MD, PhD, MPH
Institute for Clinical & Translational Science (ICTS)
To evaluate the ability of the study drug, Methotrexate to reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome who have already had at least one heart attack or have blockages in the blood vessel that supplies blood to heart.
  • Over the age of 18
  • Have had a documented heart attack within the past 5 years or have blockages in the blood vessel that supplies blood to heart
  • Have been clinically stable for at least 60 days prior to screening
  • Have either type 2 diabetes or metabolic syndrome
This is a long-term prevention trial. Participation could be for up to six years, with up to 30 study visits.
You may receive no direct benefit from being in this study. However, taking part may help you get better care in the future. The study medication may reduce the inflammation in your body, which is a known risk factor for having a heart attack; thus by participating in this study, you may prevent a future heart attack, stroke or death.
None.
Methotrexate
Drug therapy
Ashwini Erande MPH, MSc
714-456-7025